Abstract 1390P
Background
HER2 mutations (HER2m) are a potential therapeutic target in 2–3% of patients with non-squamous NSCLC; however, real-world evidence on demographics and outcomes is limited. We assessed patient characteristics and treatment patterns for advanced HER2m NSCLC at a French and a German academic centre.
Methods
Adults with advanced HER2m non-squamous NSCLC were identified at Institut Curie, France (study: 1 Jan 2011–22 Apr 2022) and Thoraxklinik Heidelberg, Germany (1 Jan 2014–5 May 2022). Lines of therapy (L) and treatment pathways were characterised. Demographic/clinical characteristics were analysed by descriptive statistics; survival was assessed by Kaplan–Meier analysis. Real-world progression-free survival (rwPFS) was time between L start and earliest progression event (Germany), discontinuation due to progression (France), next L start or death.
Results
Of 55 patients with advanced HER2m NSCLC (n=17, France; n=38, Germany), the median age at diagnosis was 66 years, 63.6% were female and 74.6% had ECOG scores of 0 or 1. 48 patients (87.3%) received at least 1L, 29 (52.7%) received at least 2L and 19 (34.5%) received at least 3L. The most common regimens were carboplatin + pemetrexed (13/48, 27.1%) and carboplatin + pemetrexed + pembrolizumab (9/48, 18.8%) in 1L and pembrolizumab (6/29, 21.0%), carboplatin + pembrolizumab + pemetrexed (3/29, 10.3%) and pemetrexed (3/29, 10.3%) in 2L. The most common treatment pathway began with non-platinum-based chemotherapy or platinum-based chemotherapy in 1L (26/48, 54.2%) and immunotherapy in 2L (7/26, 26.9%) (Table). Median real-world overall survival from the start of 1L was 16.5 months (95% CI: 12.3–29.8). Median rwPFS in the 1L was 5.1 months (95% CI: 3.5–8.5).
Conclusions
Chemotherapy was the mainstay in 1L; diverse regimens were used in 2L. Poor survival suggests a need for novel therapeutic options for advanced HER2m NSCLC. Table: 1390P
Regimen | 1L (n=48) | 2L (n=29) | 3L (n=19) | |||
n | % | n | % | n | % | |
HER2 targeteda | 1 | 2.1 | 1 | 3.4 | 4 | 21.1 |
HER2 targeteda + IMT | 0 | 0 | 0 | 0 | 1 | 5.3 |
HER2 targeteda + non-plat | 0 | 0 | 4 | 13.8 | 0 | 0 |
IMT | 3 | 6.3 | 8 | 27.6 | 1 | 5.3 |
IMT + non-HER2 targetedb + non-plat + plat | 1 | 2.1 | 0 | 0 | 0 | 0 |
IMT + non-plat + plat | 11 | 22.9 | 3 | 10.3 | 1 | 5.3 |
Non-HER2 targetedb | 1 | 2.1 | 1 | 3.4 | 0 | 0 |
Non-HER2 targetedb + non-plat | 0 | 0 | 2 | 6.9 | 2 | 10.5 |
Non-HER2 targetedb + non-plat + plat | 4 | 8.3 | 0 | 0 | 0 | 0 |
Non-plat | 1 | 2.1 | 6 | 20.7 | 7 | 36.8 |
Non-plat + plat | 26 | 54.2 | 4 | 13.8 | 3 | 15.8 |
aNeratinib, afatinib, poziotinib, trastuzumab, or trastuzumab emtansine. bAlectinib, bevacizumab, ceritinib, or ramucirumab. IMT, immunotherapy; non-plat, non-platinum-based chemotherapy; plat, platinum-based chemotherapy.
Clinical trial identification
Editorial acknowledgement
Medical writing and editorial assistance were provided by Julia C. Jones (PharmD, PhD), Erica Cave (PhD), and Daria Renshaw from IQVIA, funded by the study sponsors.
Legal entity responsible for the study
AstraZeneca, Daiichi Sankyo.
Funding
AstraZeneca, Daiichi Sankyo.
Disclosure
P. Christopoulos: Financial Interests, Personal, Advisory Board: AstraZeneca, Boehringer Ingelheim, Chugai, Pfizer, Novartis, MSD, Takeda, Roche, Daiichi Sankyo; Financial Interests, Personal, Writing Engagement: Gilead; Financial Interests, Personal, Invited Speaker: Thermo Fisher; Financial Interests, Institutional, Funding: AstraZeneca, Boehringer Ingelheim, Amgen, Novartis, Roche; Financial Interests, Personal, Funding: Takeda. N. Girard: Financial Interests, Personal, Invited Speaker: AstraZeneca, BMS, MSD, Roche, Pfizer, Mirati, Amgen, Novartis, Sanofi, Gilead; Financial Interests, Personal, Advisory Board: AstraZeneca, BMS, MSD, Roche, Pfizer, Janssen, Boehringer, Novartis, Sanofi, AbbVie, Amgen, Lilly, Grunenthal, Takeda, Owkin, Leo Pharma, Daiichi Sankyo, Ipsen; Financial Interests, Institutional, Research Grant, Local: Roche, Sivan, Janssen; Financial Interests, Institutional, Funding: BMS, Leo Pharma; Financial Interests, Institutional, Research Grant: MSD; Non-Financial Interests, Officer, International Thymic malignancy interest group, president: ITMIG; Other, Family member is an employee: AstraZeneca. L. Zhang: Financial Interests, Personal, Full or part-time Employment: Daiichi Sankyo; Financial Interests, Institutional, Funding, Funding for study and publication: Daiichi Sankyo, AstraZeneca. Z. Mbanya: Financial Interests, Personal, Full or part-time Employment: AstraZeneca. K. Dunton: Financial Interests, Personal, Full or part-time Employment: Daiichi Sankyo. A. Ali: Financial Interests, Personal, Full or part-time Employment: Daiichi Sankyo; Financial Interests, Personal, Full or part-time Employment, Prior employer: AstraZeneca. M. Berktas: Financial Interests, Personal, Other, I receive regular consultancy fee for my scientific services, I am the project lead for the project from which 2 abstracts were created and submitted to ESMO 2023 congress: AstraZeneca. L. Delmastro: Financial Interests, Personal, Full or part-time Employment: AstraZeneca; Financial Interests, Institutional, Funding, Funding for study & publication: AstraZeneca, Daiichi Sankyo. A. Struebing: Financial Interests, Personal, Full or part-time Employment: Daiichi Sankyo. Y. Xiong: Financial Interests, Personal, Full or part-time Employment: Daiichi Sankyo; Financial Interests, Personal, Full or part-time Employment, Prior employer: Becton Dickinson. S. Lay-Flurrie: Financial Interests, Personal, Full or part-time Employment: IQVIA; Financial Interests, Personal, Full or part-time Employment, Previous employer: University of Oxford; Financial Interests, Institutional, Funding, Funding for study & publication: AstraZeneca, Daiichi Sankyo. P. Hindocha: Financial Interests, Institutional, Funding, Funding for study & publication: AstraZeneca, Daiichi Sankyo; Financial Interests, Personal, Full or part-time Employment: IQVIA. T. Mehdikhanova: Financial Interests, Institutional, Funding, Funding for study and publication: AstraZeneca, Daiichi Sankyo; Financial Interests, Personal, Full or part-time Employment: IQVIA.
Resources from the same session
1453P - Trends in treatment regimens and survival in the use of immune checkpoint inhibitors for lung cancer treatment in the Netherlands from 2016-2020
Presenter: Erick Suazo Zepeda
Session: Poster session 20
1454P - Radiomic analysis predicts response to immunotherapy in metastastic non-small cell lung cancer (mNSCLC): Preliminary results
Presenter: Salvatore Grisanti
Session: Poster session 20
1455P - Nivolumab (nivo) resumption in patients with advanced or metastatic non-small cell lung cancer (aNSCLC): Survival outcomes based on France and Germany real-world data (RWD)
Presenter: Maurice Pérol
Session: Poster session 20
1456P - Exploring biological and molecular factors as outcome predictors for pembrolizumab (Pem) or pembrolizumab-chemotherapy (Pem-CT) in advanced non-small cell lung cancer (NSCLC)
Presenter: Lodovica Zullo
Session: Poster session 20
1457P - Oligometastatic non-small cell lung cancer: Impact of local and systemic treatment approaches on clinical outcome
Presenter: Marcel Wiesweg
Session: Poster session 20
1459P - Preliminary efficacy and safety of KN046 (a bispecific anti-PD-L1/CTLA-4) in patients with metastatic non-small cell lung cancer who previously treated with immune checkpoint inhibitor(s)
Presenter: Caicun Zhou
Session: Poster session 20
1460P - GALLANT-1: GB1211 galectin-3 (Gal-3) inhibitor plus atezolizumab (atz) for first line treatment in patients (pts) with advanced/metastatic non-small cell lung cancer (NSCLC)
Presenter: Francisco Aparisi Aparisi
Session: Poster session 20
1461P - Predictive value of residual FDG-PET metabolic activity in metastatic non-small cell lung cancer (mNSCLC) patients (pts) with long-lasting response to immune checkpoint inhibitors (ICIs)
Presenter: Toublanc Anne-Claire
Session: Poster session 20
1463P - IL-6 triggers chemoimmunotherapy resistance by creating immunosuppressive tumor microenvironment in non-small cell lung cancer
Presenter: Yaning Yang
Session: Poster session 20